The core therapeutic role of this medication is to provide support for significant metabolic needs in clinical settings where the body is experiencing tissue loss associated with chronic illness. Its uses are concentrated in therapeutic domains requiring the management of significant tissue deficit and systemic strengthening.

This medication is commonly used to help with symptoms in conditions such as severe tissue wasting (cachexia), postmenopausal osteoporosis linked to bone mineral density loss, and certain chronic anemias, particularly those associated with renal insufficiency. These agents provide supportive relief across key therapeutic domains.

Counteracting Severe Wasting and Physical Frailty

This medication is applied in conditions marked by a negative nitrogen balance and severe tissue wasting, such as cachexia associated with chronic kidney disease or severe systemic illness, or loss due to trauma or burns. The primary benefit is that it is applied in addressing symptoms related to physical discomfort and functional strain, which supports the patient during difficult episodes by easing distress and supports patients during difficult episodes when symptoms create noticeable physiological strain. This is relevant in contexts involving a heightened systemic burden.

Supporting Bone Density and Anemia Symptoms

The medication is considered relevant in the management of progressive loss of bone mineral density (BMD), particularly in postmenopausal osteoporosis. This therapy is relevant for easing symptoms linked to organ-specific functional stress (skeletal), which is a critical benefit that contributes to easing the overall symptom burden and may assist patients with managing the risk of skeletal compromise. Furthermore, in situations involving red blood cell deficiency (chronic anemia), it offers supportive therapeutic benefit and assists with maintaining functional stability, which assists with maintaining day-to-day comfort and easing fatigue.

---

Quick Fact: Support for Systemic Imbalance

The medication is commonly used across conditions presenting with severe catabolism, where the primary goal is to provide supportive relief to help the body address symptoms related to systemic imbalance and assists with maintaining functional stability.

Regulatory References

1. Australian NPS MedicineWise

The eligibility for Ретаболил (Nandrolone Decanoate) is strictly governed by regulatory authorities, with use permitted only for non-contraindicated adult patients requiring supportive metabolic therapy.

Populations for whom use is Contraindicated

Use is prohibited for groups where the risks are deemed unacceptable by regulatory bodies. This includes:

• Male patients with known or suspected carcinoma of the prostate or breast.
• Pregnant women or women who may become pregnant (due to the risk of fetal virilization).
• Patients with nephrosis or the nephrotic phase of nephritis.
• Patients with a history of hypersensitivity to the active substance or excipients like arachis oil.

Age-related and Conditional Use Restrictions

Population / Condition	Official Regulatory Rule
Pediatric Use	Use is not recommended; requires close bone age monitoring every six months due to the risk of premature epiphyseal closure (stunted growth).
Geriatric Male Adults	Requires special caution due to an increased risk of developing prostatic hypertrophy or carcinoma.
Organ Dysfunction	Requires special caution for patients with pre-existing cardiac, renal, or hepatic disease due to the potential for fluid retention.
Lactation	Not recommended; a decision must be made to discontinue the drug or discontinue nursing.

This eligibility structure solely addresses patient criteria as officially defined in government-approved labeling.

Interactions with other medicines and products

Official regulatory documents classify the interactions of Ретаболил (Nandrolone Decanoate) into distinct categories based on the documented outcomes and clinical constraints they impose.

Documented Interaction Categories

Interaction Type	Interacting Agent Category	Official Interaction Statement
Increased Activity	Oral Anticoagulants (e.g., Warfarin)	May increase sensitivity to anticoagulants, resulting in an elevated Prothrombin Time (PT) and INR.
Increased Activity	Antidiabetic Agents (e.g., Insulin)	May increase the hypoglycemic activities of co-administered antidiabetic medicines.
Additive Risk	Corticosteroids / ACTH	Concomitant administration may add to the edema (fluid retention), increasing the risk or severity of edema formation.
Decreased Effect	Enzyme Inducers (e.g., Rifampicin, Phenytoin)	Concurrent use may decrease the effect of Nandrolone Decanoate.

Interaction-Related Constraints and Notes

• Procedural Constraint (Monitoring): Official labeling requires close monitoring of blood parameters for two categories of interacting agents: Prothrombin Time (PT) and INR must be carefully watched when co-administering oral anticoagulants, and blood glucose levels must be monitored closely for patients on antidiabetic agents.
• Population-Specific Caution: The heightened risk of edema formation when combined with adrenal steroids/ACTH is a specific caution required for patients with pre-existing cardiac, renal, or hepatic disease.

How Ретаболил Works

The mechanism of action is centered on the selective modulation of cell function via the Androgen Receptor (AR), initiating cascading effects that drive fundamental changes in metabolism and hematopoiesis.

---

Androgen Receptor Activation and Protein Turnover

The primary action of the active molecule, Nandrolone, is to function as an agonist of the nuclear Androgen Receptor (AR) in muscle and bone. This receptor activation promotes gene transcription that increases protein synthesis while simultaneously inhibiting protein breakdown. This targeted genetic modulation establishes a state of positive nitrogen balance, which is the physiological foundation for net protein accretion.

---

Stimulation of Erythropoiesis

A secondary mechanistic domain involves the stimulation of Erythropoietin (EPO) production, primarily in the kidneys. The subsequent elevation in circulating EPO acts on the bone marrow, accelerating the differentiation and maturation of red blood cell precursors. This cascade results in an increase in red blood cell mass and overall blood volume, which determines the systemic oxygen-carrying capacity.

---

Pharmacologic Constraint by Decanoate Ester

The drug’s prolonged activity is due to the chemical structure incorporating the decanoate ester. This chemical modification ensures that, following intramuscular injection, the active drug is only released through the slow, continuous enzymatic hydrolysis of the ester at the injection site. This mechanism is critical because it facilitates sustained systemic exposure of the active Nandrolone molecule to the target receptors over several weeks, which contributes to the persistence of the physiological changes.

How to Use Ретаболил: Official Administration Guidelines

Ретаболил (Nandrolone Decanoate) is administered based on clinical protocols that determine its route, dosage, frequency, and duration of use. As a long-acting oily solution, the administration is designed to ensure a sustained therapeutic effect.

Administration Route and Method

• Route: The designated route is deep intramuscular injection (IM). The injection is typically administered into a large muscle mass, such as the gluteal muscle (buttock), and is intended to be performed only by a doctor or trained healthcare professional.
• Form: The medicine is provided as a sterile oily solution for injection in strengths such as 50 mg/mL and 100 mg/mL.

Standard Dosing and Frequency

Dosing regimens vary depending on the condition being supported. The schedule reflects the drug's sustained-action properties.

Indication	Standard Adult Dosing	Frequency
Anemia of Renal Disease	Males: 100 to 200 mg / Females: 50 to 100 mg	Once per week
Postmenopausal Osteoporosis	50 mg	Every 2 to 3 weeks

Course Duration and Contextual Instructions

Therapy is generally structured around intermittent courses of treatment. For conditions like anemia, if no satisfactory improvement is observed within the first six months, discontinuation is typically considered. A critical contextual instruction is that the medicine is classified as adjunctive therapy, requiring patients to maintain adequate nutritional intake, including sufficient protein and calories, for the drug to provide its intended effect.

Research evidence / Overview of studies for Ретаболил

Evidence for use in Severe Tissue Wasting (Cachexia)

Studies were evaluated in adults experiencing tissue loss or severe catabolic states, such as those with HIV-related wasting or patients undergoing dialysis. Research explored physiological changes and utilized short-term Randomized Controlled Trials (RCTs) and open-label study designs. The focus was on outcomes related to systemic or functional imbalance, specifically monitoring physiological strain or stress by measuring changes in Lean Body Mass (LBM) and Fat-Free Mass.

Studies monitored changes in LBM, with findings describing patterns where measurements of LBM shifts were reported in the observed populations during the study period. Reported outcomes were limited to these physiological shifts and corresponding weight changes.

However, the evidence is limited regarding long-term functional outcomes, such as sustained mobility or daily activity level. Follow-up durations were limited, meaning there is limited information for long-term outcomes. Sample sizes were modest in many trials, and comparative evidence against other agents studied for catabolism is lacking.

Evidence for use in Postmenopausal Osteoporosis and Sarcopenia

Older trials and systematic reviews were applied in studies involving postmenopausal women and older adults. Research focused on monitoring Bone Mineral Density (BMD) at key skeletal sites over defined time intervals, and examined outcomes reflecting physical discomfort. Researchers also studied for any changes in the rate of new vertebral fractures.

Studies described patterns related to BMD measurements, which were reported to have evolved in the observed populations. Research highlights changes measured during the study period, including observations of how fracture rates evolved in the observed populations compared to control groups.

Evidence quality varies across studies, as much of this research is historical and used older methodologies. Long-term effects are not fully established regarding the persistence of measured changes after treatment ends. Comparative evidence against other agents studied for osteoporosis is lacking.

What Remains Uncertain and Future Research Gaps

The research base contributes to the broader evidence landscape but also highlights what is still uncertain. Evidence quality varies across studies, and many defining trials have follow-up durations that were limited. Sample sizes were modest in some of the key studies. Consequently, comparative evidence is lacking against recently introduced therapeutic options, and there is limited information for long-term outcomes. Research provides context but not individual predictions.

Key Studies & References

1. Anabolic Steroids and Exercise in Hemodialysis Patients (NCT00250536) - Clinical Trial Summary
2. Nandrolone Decanoate Injection - DailyMed Monograph

Common questions about Ретаболил (FAQ)

Q: Is Ретаболил the same as other medicines that treat similar conditions?

According to the official classification, Ретаболил is an anabolic-androgenic steroid (AAS). The active substance, Nandrolone, is a synthetic derivative known as a 19-nor compound. Regulatory documents describe this specialized structure as designed to provide an anabolic (tissue-building) to androgenic activity profile different from some other anabolic agents.

Q: Does Ретаболил interact with common over-the-counter pain relievers?

Official product information specifies clinically significant interactions with certain categories of medicines, such as oral anticoagulants, antidiabetic agents, and adrenal steroids (corticosteroids). Regulatory documents typically do not contain a specific statement regarding potential interactions with common, non-prescription pain relievers.

Q: Does taking Ретаболил require special monitoring or blood tests?

Yes, official regulatory documents require close monitoring of various health parameters due to the drug’s potential systemic effects. This monitoring typically involves checking liver function, blood lipid profiles, blood glucose levels, and blood clotting time (PT/INR). Monitoring may also be required for signs of fluid retention or virilization (masculinizing effects).

Q: How long after stopping Ретаболил does the substance typically remain in the body?

As a long-acting injection, the drug is designed for slow release from the muscle injection site. The prolonged release of the active compound has a half-life cited in official documents as approximately 6 days. This prolonged half-life contributes to the drug's sustained presence following administration.

Q: Are the side effects of Ретаболил generally reversible after stopping the medication?

The official safety information notes that certain adverse effects are associated with prolonged therapy. Regulatory documents specifically caution that some side effects, such as virilization (masculinizing changes) in women, may be irreversible even after the medicine is discontinued.

Q: Why is Ретаболил sometimes mentioned in relation to anabolic effects?

The medicine is classified as an anabolic-androgenic steroid. This classification is due to its mechanism, where its active ingredient promotes processes that lead to protein synthesis and the maintenance of a positive nitrogen balance. These processes support the drug's tissue-building, or anabolic, effects.

Q: What is meant by the half-life of Ретаболил?

Half-life is the scientific measurement used to describe the time it takes for the concentration of the drug in the bloodstream to be reduced by half. Since Ретаболил is a long-acting injection, this measurement helps indicate how long the medicine’s therapeutic presence is sustained in the body.

Q: How quickly does Ретаболил start working after the first dose?

The formulation is an oily solution specifically designed for slow, continuous release of the active ingredient after deep intramuscular injection. Because of this mechanism, the therapeutic effect builds up gradually over a period of time rather than having an immediate onset after the first dose.

Q: Does Ретаболил need to be taken at a specific time of day?

Official instructions define the drug’s route of administration (deep intramuscular injection) and the necessary frequency (such as weekly or bi-weekly administration). However, official documentation typically does not mandate a specific time of day for when the injection must be performed.

Q: Are there any foods or drinks that should be avoided when taking Ретаболил?

Regulatory documents require patients to maintain adequate nutritional intake, including sufficient protein and calories, for the medicine to achieve its intended effect. The prescribing information generally does not list specific foods or drinks that must be strictly avoided during therapy.

Q: Can Ретаболил cause weight gain or weight loss?

The drug’s mechanism of action involves promoting protein synthesis and establishing a positive nitrogen balance, which is the physiological basis for increasing lean body mass (LBM). Changes in body weight corresponding to shifts in LBM were monitored during clinical studies.

Q: Is Ретаболил safe for older adults or elderly patients?

Official documents indicate that special caution is necessary for geriatric male adults due to an increased risk of developing prostatic hypertrophy or carcinoma. Caution is also noted for all patients with pre-existing cardiac, kidney, or liver disease due to the potential for fluid retention.

Q: What kind of research has been done on the long-term effects of Ретаболил?

Studies have included Randomized Controlled Trials (RCTs) and open-label designs. The research focused on physiological outcomes such as changes in Lean Body Mass (LBM), Fat-Free Mass (FFM), and Bone Mineral Density (BMD). Official information indicates that evidence regarding long-term functional outcomes beyond the study duration is limited.

Q: Does Ретаболил affect sleep or energy levels?

Adverse reactions listed in official documents include effects on the Central Nervous System (CNS), such as insomnia (difficulty sleeping).

Q: Is it common to feel nausea when starting Ретаболил?

Some official documents list nausea as a reported side effect, alongside other reactions like itching or injection site reactions. Additionally, severe or persistent nausea is noted as a symptom to monitor for, as it can be associated with serious adverse effects.

Q: How is the effectiveness of Ретаболил measured in clinical studies?

In clinical studies, effectiveness is measured by monitoring physiological changes related to the drug's mechanism of action. This includes changes in Lean Body Mass (LBM), Bone Mineral Density (BMD), and parameters associated with the production of red blood cell mass.

Q: Can women use Ретаболил, and are there specific warnings for them?

The drug has been officially approved for use in women for certain conditions, such as postmenopausal osteoporosis. Warnings exist regarding the potential for virilization (masculinizing effects), which should be closely monitored in female patients.

Q: Does taking Ретаболил affect a person's ability to drive or operate machinery?

Official prescribing information generally does not contain a specific warning that the drug impairs the ability to drive or operate heavy machinery.

Q: What is the difference in effect between a low dose and a high dose of the drug?

The official product information specifies the authorized therapeutic range for adults based on the condition being supported (e.g., 50 mg to 200 mg per dose). The dose is carefully managed within this defined range to optimize the therapeutic effect.

Q: Why is it important to tell the doctor about all other medicines when starting Ретаболил?

This reporting is required because Ретаболил is known to interact with certain drug categories, such as oral anticoagulants and antidiabetic agents. These interactions can change the effects of those medicines and necessitate careful monitoring by a healthcare professional.

The storage and disposal of Nandrolone Decanoate injection must align with regulatory requirements to preserve product stability and ensure controlled handling.

Storage Requirements

Condition	Requirement
Temperature	Store at Controlled Room Temperature, typically 20 C to 25 C (68 F to 77 F); avoid freezing [2.3].
Protection	Keep in the original carton until use to protect the solution from light [2.3].
Vial Integrity	The solution must be visually inspected before use and must not be used if it contains crystals or particulate matter [1.2, 2.3].
Child Safety	The medication must be kept well out of the reach of children [2.3].

Disposal Instructions

As a Schedule III controlled substance, the product requires specific handling [2.3]. Any expired or unused solution must be disposed of according to local regulatory requirements and specific instructions provided by the clinic or dispensing pharmacy [1.2]. These specialized instructions must be followed to prevent misuse and environmental contamination.